K.H. Njo

742 total citations
18 papers, 566 citations indexed

About

K.H. Njo is a scholar working on Pulmonary and Respiratory Medicine, Otorhinolaryngology and Oncology. According to data from OpenAlex, K.H. Njo has authored 18 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Otorhinolaryngology and 6 papers in Oncology. Recurrent topics in K.H. Njo's work include Lung Cancer Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Head and Neck Cancer Studies (5 papers). K.H. Njo is often cited by papers focused on Lung Cancer Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Head and Neck Cancer Studies (5 papers). K.H. Njo collaborates with scholars based in Netherlands and United States. K.H. Njo's co-authors include Ben J. Slotman, Alavi Karim, A.B.M.F. Karim, G. B. Snow, Arie Hasman, Jan B. Vermorken, Herbert M. Pinedo, R. M. Tiwari, Otto W.M. Meijer and A. de Jonge and has published in prestigious journals such as Cancer, International Journal of Radiation Oncology*Biology*Physics and Radiotherapy and Oncology.

In The Last Decade

K.H. Njo

18 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.H. Njo Netherlands 12 297 191 163 157 153 18 566
Emmanuelle Tresch France 15 313 1.1× 116 0.6× 173 1.1× 175 1.1× 213 1.4× 45 628
Voichita Bar Ad United States 12 176 0.6× 99 0.5× 221 1.4× 60 0.4× 173 1.1× 43 484
B. Fortin Canada 20 382 1.3× 344 1.8× 178 1.1× 210 1.3× 254 1.7× 43 767
Tuija Wigren Finland 12 235 0.8× 154 0.8× 142 0.9× 127 0.8× 73 0.5× 20 502
Heerim Nam South Korea 15 295 1.0× 88 0.5× 267 1.6× 103 0.7× 349 2.3× 36 724
Irene Karam Canada 19 272 0.9× 249 1.3× 265 1.6× 120 0.8× 157 1.0× 96 836
Elisa D’Angelo Italy 14 214 0.7× 114 0.6× 81 0.5× 117 0.7× 186 1.2× 40 536
Pètra M. Braam Netherlands 13 396 1.3× 366 1.9× 168 1.0× 238 1.5× 234 1.5× 41 745
Charles Gillham Ireland 14 425 1.4× 64 0.3× 143 0.9× 217 1.4× 425 2.8× 50 957
William R. Rate United States 13 180 0.6× 79 0.4× 212 1.3× 56 0.4× 186 1.2× 31 534

Countries citing papers authored by K.H. Njo

Since Specialization
Citations

This map shows the geographic impact of K.H. Njo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.H. Njo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.H. Njo more than expected).

Fields of papers citing papers by K.H. Njo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.H. Njo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.H. Njo. The network helps show where K.H. Njo may publish in the future.

Co-authorship network of co-authors of K.H. Njo

This figure shows the co-authorship network connecting the top 25 collaborators of K.H. Njo. A scholar is included among the top collaborators of K.H. Njo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.H. Njo. K.H. Njo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Slotman, Ben J., et al.. (1996). Limited field irradiation in early stage (T1–2N0) non-small cell lung cancer. Radiotherapy and Oncology. 41(1). 41–44. 84 indexed citations
2.
Njo, K.H., et al.. (1995). Results of radiotherapy and vitamin E in the treatment of Peyronie's disease. International Journal of Radiation Oncology*Biology*Physics. 31(3). 571–576. 23 indexed citations
3.
Slotman, Ben J., et al.. (1994). Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer. Radiotherapy and Oncology. 30(3). 206–212. 76 indexed citations
4.
Slotman, Ben J., et al.. (1994). Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 29(1). 33–37. 54 indexed citations
5.
Njo, K.H., et al.. (1993). Hypofractionation radiotherapy for a locally recurrent rectal carcinoma as a treatment for an elderly patient. Supportive Care in Cancer. 1(6). 334–335. 4 indexed citations
6.
Slotman, Ben J., K.H. Njo, A. de Jonge, Otto W.M. Meijer, & A.B.M.F. Karim. (1993). Palliative radiotherapy in advanced metastatic and non-metastatic non-small cell lung cancer. Lung Cancer. 8(5-6). 285–292. 3 indexed citations
7.
Njo, K.H., et al.. (1993). Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer. 10(3-4). 221–228. 31 indexed citations
8.
Slotman, Ben J., K.H. Njo, A. de Jonge, Otto W.M. Meijer, & A.B.M.F. Karim. (1993). Hypofractionated radiation therapy in unresectable stage iii non-small cell lung cancer. Cancer. 72(6). 1885–1893. 26 indexed citations
9.
Slotman, Ben J., et al.. (1993). Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer. Lung Cancer. 10(3-4). 199–208. 1 indexed citations
10.
Karim, A.B.M.F., et al.. (1990). A critical look at the TNM classification for laryngeal carcinoma. Cancer. 65(9). 1918–1922. 7 indexed citations
11.
Karim, Alavi, et al.. (1990). Ethmoid and upper nasal cavity carcinoma: treatment, results and complications. Radiotherapy and Oncology. 19(2). 109–120. 33 indexed citations
12.
Boven, Epie, Jan B. Vermorken, Henk van Deutekom, et al.. (1987). Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics. 13(11). 1735–1738. 27 indexed citations
13.
Karim, Alavi, et al.. (1987). Radiation therapy for advanced (T3T4N0-N3M0) laryngeal carcinoma: the need for a change of strategy: A radiotherapeutic viewpoint. International Journal of Radiation Oncology*Biology*Physics. 13(11). 1625–1633. 48 indexed citations
14.
Karim, Alavi, Liang Yap, K.H. Njo, et al.. (1987). Heterogeneity of stage II glottic carcinoma and its therapeutic implications. International Journal of Radiation Oncology*Biology*Physics. 13(3). 313–317. 37 indexed citations
15.
Balm, A. J. M., et al.. (1986). Long-Term Results of Concurrent Polychemotherapy and Radiotherapy in Patients with Stomal Recurrence after Total Laryngectomy. Annals of Otology Rhinology & Laryngology. 95(6). 572–575. 11 indexed citations
16.
Keizer, H.J., A.B.M.F. Karim, K.H. Njo, et al.. (1984). Feasibility study on daily administration of cis-diamminedichloroplatinum(II) in combination with radiotherapy. Radiotherapy and Oncology. 1(3). 227–234. 35 indexed citations
17.
Karim, Alavi, et al.. (1983). The quality of voice in patients irradiated for laryngeal carcinoma. Cancer. 51(1). 47–49. 63 indexed citations
18.
Karim, A.B.M.F., et al.. (1980). Metronidazole as a radiosensitizer: A preliminary report on estimation in serum and saliva. International Journal of Radiation Oncology*Biology*Physics. 6(9). 1233–1236. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026